Philips ventilator recall troubles deepen as USFDA finds new issues
New Delhi: The U.S. Food and Drug Administration (FDA) has asked Philips to conduct more tests on the foam used in its recalled ventilators, after the agency found several new issues at the Dutch company's manufacturing facility.
The medical equipment company recalled some breathing devices and ventilators in June because of a silicone-based foam part that might degrade and become toxic, potentially causing cancer.
The FDA noted, in a so-called form 483, that between April 2016 and January 2021, Philips was aware of 14 instances of issues related to potential foam degradation with its different sleep and respiratory devices.
Philips, which in September said it will repair and replace the 15 million devices recalled globally, did not immediately respond to a request for comment.
The company has not sufficiently demonstrated that other devices containing this foam should not also be recalled, and its risk analysis was inadequate, the agency said in the form.
Read also: Philips ventilator recall classified as most serious by USFDA
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.